JP Morgan Goes “Back In Time” — On “New” Merck Price Target


So JP Morgan has moved Merck’s 12 month stock price target up to. . . where JP Morgan had it in January of 2010 (per a PDF transcript of the 2010 JP Morgan Healthcare conference) — from $42 to $44. Yawn. This isn’t really any news at all, but it is courtesy of Benzinga:

. . . .We are increasing our MRK sales and EPS estimates following strong 1Q/11 results. Our new estimates are toward the high end of the company’s 2011 guidance range. We are raising our PT by $2 to $44.

J.P. Morgan maintains Overweight on Merck. . . .

Uh-huh, Sure it does — it also has more than ample reason to curry favor, as I’ve repeatedly pointed out in the past.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s